fbpx

Myxedema Coma

Updated : August 26, 2022





Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

 

levothyroxine

300 - 500

mcg

Intravenous (IV)

once a day


Or 50-100 mcg once a day until patient can tolerate



liothyronine 

25-50 mcg intravenously
Patients with cardiovascular disease, 10-20 mcg intravenously
For lower mortality rate, 65 mcg/day intravenously
Keep an interval of 4-12 hours in between the doses, do not exceed more than 12 hours



 
 

Media Gallary

References

Myxedema Coma

Updated : August 26, 2022




levothyroxine

300 - 500

mcg

Intravenous (IV)

once a day


Or 50-100 mcg once a day until patient can tolerate



liothyronine 

25-50 mcg intravenously
Patients with cardiovascular disease, 10-20 mcg intravenously
For lower mortality rate, 65 mcg/day intravenously
Keep an interval of 4-12 hours in between the doses, do not exceed more than 12 hours